Characteristics and outcome of the COEUR Canadian validation cohort for ovarian cancer biomarkers

BMC Cancer

Table 4 Univariate Cox regression model of histotypes on disease specific survival

Histotype	All cases					Advanced stage					Poor prognosis					Low stage
	Hazard	95.0% CI		n		Hazard	95.0% CI		n		Hazard	95.0% CI		n		Hazard	95.0% CI
	Ratio	Lower	Upper		p value	Ratio	Lower	Upper		p value	Ratio	Lower	Upper		p value	Ratio	Lower	Upper	n	p value
HGSC				1216	reference				940	reference				621	reference				206	reference
EC	0.19	0.14	0.26	274	0.000	0.51	0.34	0.77	49	0.001	0.85	0.48	1.51	18	0.575	0.20	0.12	0.34	214	0.000
LGSC	0.62	0.47	0.81	101	0.001	0.67	0.50	0.91	73	0.009	0.72	0.50	1.03	49	0.069	0.68	0.31	1.48	20	0.332
CCC	0.51	0.41	0.62	255	0.000	1.63	1.24	2.16	65	0.001	1.54	1.00	2.36	27	0.050	0.62	0.43	0.89	178	0.01
MC	0.35	0.23	0.53	86	0.000	2.95	1.58	5.52	11	0.001	13.82	6.41	29.79	7	0.000	0.48	0.26	0.88	72	0.017

Bold values highlights the adjusted statistically significant difference with the reference category
EOC epithelial ovarian cancer, n number of patients with follow-up, CI confidence interval, low stage: patients with stage I and II, advanced stage: patients with stage III and IV, HGSC High-Grade Serous Carcinoma, EC Endometrioid Carcinoma, LGSC Low-Grade Serous Carcinoma

ISSN: 1471-2407